$VTGN

Vistagen Therapeutics, Inc. (VTGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Amendment and Restatement of Executive Severance Plan On October 7, 2026, the Board of Directors (the “ Board ”) of Vistage

Vistagen (VTGN) reported positive exploratory findings for Fasedienol, its intranasal treatment for very severe social anxiety disorder, at Psych Congress 2026. Analyses from two trials showed improvements in anxiety symptoms compared to placebo. The company's stock has traded between $0.20 and $5.14 in the past year, currently at $0.30.

Vistagen Therapeutics, Inc. (VTGN) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder Exploratory research results presented at Psych Congress 2026 in New Orleans Full poster presentation can be found on “Publications” section of Company’s websi

Worthington Enterprises (NYSE:WOR) shares rose 15.9% in pre-market trading after reporting Q1 earnings of $0.82 per share, beating estimates of $0.75, and sales of $343.89M, exceeding expectations of $331.27M.

Vistagen Therapeutics, Inc. (VTGN) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Fasedienol nasal spray was well-tolerated in patients with social anxiety disorder with no new

Vistagen Therapeutics, Inc. (VTGN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On September 10, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) held its 2026 Annual Meeting of Stockholders (the “ 2026 Annual Meeting ”). At the 2026 Annual Meeting, as set forth below, the Company’s stockholde

Vistagen Therapeutics, Inc. (VTGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies FDA eng

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

SRX Global Inc. (SRXH) said it acquired a stake in Vistagen Therapeutics (VTGN), a late clinical-stage neuroscience biopharma developing intranasal “pherines” for CNS disorders. SRXH said it views VTGN as undervalued and plans constructive engagement with management and the board. VTGN closed at $0.24 and was $0.37 in pre-market.

Vistagen Therapeutics, Inc. (VTGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EXHIBIT 99.1 Vistagen Appoints Douglas J. Williamson to its Board of Directors Dr. Williamson brings nearly three decades of leadership experience in neuroscience drug development, clinical research, and regulatory strategy SOUTH SAN FRANCISCO, Calif.--(GLOBE NEWSWIRE)—July 31, 2